Literature DB >> 10520784

Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential.

R C Becker1, F A Spencer, Y Li, S P Ball, Y Ma, T Hurley, J Hebert.   

Abstract

OBJECTIVES: The purpose of this study was to determine the mechanistic basis for thrombin generation and increased prothrombotic potential after the abrupt cessation of intravenous (i.v.) unfractionated heparin among patients with acute coronary syndromes.
BACKGROUND: A "rebound" increase in prothrombotic potential has been observed biochemically and clinically after the abrupt cessation of unfractionated heparin (UFH) among patients with acute coronary syndromes. Although the mechanism is unknown, tissue factor and the extrinsic coagulation cascade, both operative in atherosclerotic vascular disease and arterial thrombosis, are thought to be centrally involved.
METHODS: In a single-center, pilot study, 30 patients with either unstable angina or non-ST segment elevation myocardial infarction who had received a continuous i.v. infusion of UFH for 48 h were randomly assigned to: 1) abrupt cessation, 2) i.v. weaning over 12 h or 3) subcutaneous weaning over 12 h.
RESULTS: Thrombin generation (prothrombin fragment 1.2) was evident within 1 h of UFH cessation, increased progressively (by nearly two-fold) at 24 h (p = 0.002) and correlated inversely with tissue factor pathway inhibitor concentration (r = -0.61). Thrombin generation was greatest among patients randomized to abrupt cessation (1.6-fold increase at 24 h) and least in those with i.v. weaning.
CONCLUSIONS: Thrombin generation after the abrupt cessation of UFH may represent a drug-induced impairment of physiologic vascular thromboresistance in response to locally generated tissue factor. A dosing strategy of abbreviated i.v. weaning attenuates but does not prevent heparin rebound among patients with acute coronary syndromes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520784     DOI: 10.1016/s0735-1097(99)00322-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Factor Xa-A pleuripotential protease.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 2.  Choice of agents to limit the coagulation cascade in acute coronary syndromes.

Authors:  Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

3.  Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.

Authors:  David J Schneider; Burton E Sobel
Journal:  J Thromb Thrombolysis       Date:  2008-07-08       Impact factor: 2.300

4.  Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.

Authors:  Richard C Becker; John H Alexander; Youfu Li; Thomas Robertson; Satoshi Kunitada; Frederick A Spencer; Hongqiu Yang; Robert A Harrington
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

5.  Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: a meta-analysis of randomized clinical trials.

Authors:  M T Le Nguyen; F A Spencer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

6.  Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.

Authors:  YouFu Li; Miguel Rodriquez; Frederick A Spencer; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2002-10       Impact factor: 2.300

7.  A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery.

Authors:  Pranjal H Desai; Dinesh Kurian; Nannan Thirumavalavan; Sneha P Desai; Pluen Ziu; Michael Grant; Charles White; R Clive Landis; Robert S Poston
Journal:  Anesth Analg       Date:  2009-11       Impact factor: 5.108

8.  Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition.

Authors:  Zachary N Kon; Emile N Brown; Michael C Grant; Toshinaga Ozeki; Nicholas S Burris; Michael J Collins; Michael H Kwon; Robert S Poston
Journal:  Eur J Cardiothorac Surg       Date:  2008-02       Impact factor: 4.191

9.  Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.

Authors:  Mitchell Levy; Marcel Levi; Mark D Williams; Massimo Antonelli; Dazhe Wang; Mariano Alejandro Mignini
Journal:  Intensive Care Med       Date:  2009-04-15       Impact factor: 17.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.